LOXL3 and hepatocellular carcinoma: For the aim to increase chemosensitivity and reduce the toxicity triggered by chemotherapeutic drugs, we introduced the low-dose treatment into our study to investigate whether LOXL3 deficiency still sensitizes HCC cells to the low-dose Oxaliplatin treatment by inducing ferroptosis, which was confirmed by measuring lipid peroxidation (Supplementary Fig. 1p).